ÄϹ¬NG28¼¯ÍÅ

nyba
ѧ¿Æ½¨Éè
Ê×Ò³ > ѧ¿Æ½¨Éè > ÕýÎÄ
ѧ¿Æ½¨Éè
ѧ¿Æ½¨Éè

ÄϹ¬NG28¼¯ÍÅÐÜÐ˶«½ÌÊÚÔÚMolecular Therapy-Nucleic Acids½ÒÏþÂÛÎÄÕ¹ÏÖеÄѪ¹ÜÄÚÆ¤Ï¸°ûÐàÂõµ÷¿Ø»úÖÆ

ȪԴ £º£º ʱ¼ä £º£º2021-09-28µã»÷ £º£º

¿ËÈÕ£¬£¬ÄϹ¬NG28¼¯ÍÅÐàÂõÑо¿ËùÐÜÐ˶«½ÌÊÚÍŶÓÒÔÄϹ¬NG28¼¯ÍÅΪΨһͨѶµ¥Î»ÔÚ¹ú¼Ê×ÅÃûѧÊõÆÚ¿¯Molecular Therapy-Nucleic Acids(ÖпÆÔº¶þÇø£¬£¬IF=8.889)ÉϽÒÏþÁË×îÐÂÑо¿Ð§¹û£¢circGNAQ, a circular RNA enriched in vascular endothelium, inhibits endothelial cell senescence and atherosclerosis progression£¢¡£¡£¡£¸ÃÑо¿Ê×´ÎÕ¹ÏÖÁË»·×´RNA circGNAQͨ¹ýcircGNAQ/miR-146a-5p/PLK2ÐźÅͨ·µ÷¿ØÑª¹ÜÄÚÆ¤Ï¸°ûÐàÂõ£¬£¬ÑÓ»º¶¯ÂöÖàÑùÓ²»¯µÄ±¬·¢¡£¡£¡£

0F48386B9D2EE211F030C55B82C_5EAEA275_1BA35

¶¯ÂöÖàÑùÓ²»¯¡¢¡¢¡¢¹ÚÐIJ¡µÈÐÄѪ¹Ü¼²²¡ÒѳÉΪÍþвÎÒ¹ú¹«ÖÚ¿µ½¡µÄÖ÷Òª¼²²¡¡£¡£¡£Ñª¹ÜË¥×ÜÊÇÕâЩÐÄѪ¹Ü¼²²¡µÄÖ÷ҪΣÏÕÒòËØ¡£¡£¡£¶øÑª¹ÜÄÚÆ¤Ï¸°ûË¥×ÜÊÇѪ¹ÜÐàÂõµÄ»ù´¡£¬£¬ÑÓ»ºÑª¹ÜÄÚÆ¤Ï¸°ûÐàÂõ¿ÉÓÐÓÃÔ¤·ÀºÍïÔÌ­ÕâЩÐÄѪ¹Ü¼²²¡µÄ±¬·¢¡£¡£¡ £»£»£»·×´RNA£¨circular RNA, circRNA£©ÊÇÒ»Àà¾ßÓбպϻ·×´½á¹¹µÄÄÚÔ´ÐÔRNA·Ö×Ó£¬£¬Ö÷ÒªÓÉǰÌåRNA£¨pre-mRNA£©Í¨¹ý¿É±ä¼ôÇмӹ¤±¬·¢¡£¡£¡£ËüÆÕ±é±£´æÓÚÖÖÖÖϸ°ûÖУ¬£¬¾ßÓбí´ïƷò¸ß¡¢¡¢¡¢½á¹¹Îȹ̺Í×éÖ¯ÌØÒìÐÔ±í´ïµÈÌØÕ÷¡£¡£¡£±¾Ñо¿Ê¹ÓøßͨÁ¿²âÐòÊÖÒÕɸѡ³öÔÚѪ¹ÜÄÚÆ¤Ï¸°ûÐàÂõÀú³ÌÖвî±ð±í´ïµÄcircRNAs£¬£¬Í¨¹ýÌåÍâʵÑé֤ʵÆäÖÐcircGNAQ¿ÉÒÔÎü¸½miR-146a-5p£¬£¬×è¶ÏmiR-146a-5p¶ÔÆäÏÂÓΰлùÒòPLK2µÄÒÖÖÆ×÷Ó㬣¬½ø¶øÑÓ»ºÑª¹ÜÄÚÆ¤Ï¸°ûµÄÐàÂõ¡£¡£¡£Í¬Ê±£¬£¬ÌåÄÚʵÑé·¢Ã÷circGNAQÔÚѪ¹ÜÄÚÆ¤ÖÐÌØÒìÐԸ߱í´ï£¬£¬ÇÒÆä±í´ïËæ×Ŷ¯ÂöÖàÑùÓ²»¯Àú³Ì³ÖÐøÏµ÷ £»£»£»ÔÚASÄ£×ÓСÊóµÄѪ¹ÜÄÚÆ¤Ï¸°ûÖÐÌØÒì¹ý±í´ïcircGNAQ¿ÉÒÔÏÔ×ÅÑÓ»ºÑª¹ÜÐàÂõºÍïÔÌ­¶¯ÂöÖàÑùÓ²»¯µÄ±¬·¢¡£¡£¡£±¾Ñо¿Õ¹ÏÖÁËcircGNAQµ÷¿ØÑª¹ÜÄÚÆ¤Ï¸°ûÐàÂõµÄ×÷ÓûúÖÆ£¬£¬ÎªÑÓ»ºÑª¹ÜÐàÂõ¡¢¡¢¡¢Ô¤·ÀºÍÖÎÁƶ¯ÂöÖàÑùÓ²»¯ÌṩеÄ˼Ð÷ºÍÖÎÁÆÕ½ÂÔ¡£¡£¡£

21CC0827C2331302EC3BB4C68E8_4C6B190B_1BC00

¸ÃÑо¿»ñµÃ¹ú¼Ò×ÔÈ»¿ÆÑ§»ù½ð¡¢¡¢¡¢¹ã¶«Ê¡×ÔÈ»¿ÆÑ§»ù½ð¡¢¡¢¡¢¶«Ý¸¿Æ¼¼Á¢ÒìÁìÎäÊ¿²Å¼°ÄϹ¬NG28¼¯ÍÅѧ¿Æ½¨ÉèÏîÄ¿µÄ×ÊÖú¡£¡£¡£Ñо¿ÉúÎ×ΰÅô¡¢¡¢¡¢ÖÜÃÈæÂ¡¢¡¢¡¢Áõ¶«ÁÁºÍãÉÑ©ÊǸÃÂÛÎĵÄÅäºÏµÚÒ»×÷Õߣ¬£¬Í¨Ñ¶×÷ÕßΪÐÜÐ˶«½ÌÊÚ¡£¡£¡£

50C62AB8030B354102D5485B931_A0E2818C_18EBE

£¨ÎÄ¡¢¡¢¡¢Í¼/ÉÛÍ© ±à/ÖÜÔ² Éó/·ë½õɽ£©

¡¾¹Ø±Õ¡¿

×îÐÂÐÂÎÅ
¡¾ÍøÕ¾µØÍ¼¡¿